1005783-07-2

Upstream product

• 1005780-65-3 N-(6-iodoimidazo[1,2-b]pyridazin-2-yl)-3-(trifluoromethyl)benzamide 
• 591-27-5 m-Hydroxyaniline 
• 1005785-71-6 6-iodo-imidazo[1,2-b]pyridazin-2-ylamine 
• 1005785-69-2 ethyl (6-iodoimidazo[1,2-b]pyridazin-2-yl)carbamate 

Downstream Products

• 1005783-70-9 C₂₇H₁₇F₄N₅O₃ 

Relevant academic research and scientific papers

Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin- 6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor

Vascular endothelial growth factor (VEGF) plays important roles in tumor angiogenesis, and the inhibition of its signaling pathway is considered an effective therapeutic option for the treatment of cancer. In this study, we describe the design, synthesis, and biological evaluation of 2-acylamino-6-phenoxy-imidazo[1,2-b]pyridazine derivatives. Hybridization of two distinct imidazo[1,2-b]pyridazines 1 and 2, followed by optimization led to the discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl} oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (23a, TAK-593) as a highly potent VEGF receptor 2 kinase inhibitor with an IC50 value of 0.95 nM. The compound 23a strongly suppressed proliferation of VEGF-stimulated human umbilical vein endothelial cells with an IC50 of 0.30 nM. Kinase selectivity profiling revealed that 23a inhibited platelet-derived growth factor receptor kinases as well as VEGF receptor kinases. Oral administration of 23a at 1 mg/kg bid potently inhibited tumor growth in a mouse xenograft model using human lung adenocarcinoma A549 cells (T/C = 8%).

FUSED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the formula (I): wherein ring A is a ring which is optionally further substituted; R1 is a hydrogen atom or a substituent; R2 is a hydrogen atom or a substituent; R3